OncRef

Clinical Trial: NCT02315612

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Institutes of Health Clinical Center (CC)
Last Update Posted:2026-04-28

Study Overview

Brief Summary

Background:

- One type of cancer therapy takes blood cells from a person, changes them in a lab, then gives the cells back to the person. In this study, researchers are using an anti-CD22 gene, a virus, and an immune receptor to change the cells.

Objective:

- To see if giving anti-CD22 Chimeric Antigen Receptor (CAR) cells to young people with certain cancers is safe and effective.

Eligibility:

- People ages 1-39 with a leukemia or lymphoma that has not been cured by standard therapy.

Design:

  • Participants will be screened to ensure their cancer cells express the CD22 protein. They will also have medical history, physical exam, blood and urine tests, heart tests, scans, and x-rays. They may give spinal fluid or have bone marrow tests.
  • Participants may have eye and neurologic exams.
  • Participants will get a central venous catheter or a catheter in a large vein.
  • Participants will have white blood cells removed. Blood is removed through a needle in an arm. White blood cells are removed. The rest of the blood is returned by needle in the other arm.
  • The cells will be changed in a laboratory.
  • Participants will get two IV chemotherapy drugs over 4 days. Some will stay in the hospital for this.
  • All participants will be in the hospital to get anti-CD22 CAR cells through IV. They will stay until any bad side effects are gone.
  • Participants will have many blood tests. They may repeat some screening exams.
  • Participants will have monthly visits for 2-3 months, then every 3-6 months. They may repeat some screening exams.
  • Participants will have follow-up for 15 years.

Official Title

Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

Conditions

NHL, Large Cell Lymphoma, Follicular Lymphoma, ALL, B-All, B-precursor ALL, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, B-Non Hodgkin Lymphoma, B-NHL

Intervention / Treatment

  • Biological: CD22-CAR

Other Study ID Numbers

  • 150029
  • 15-C-0029

Start Date (Actual)

2014-12-12

Primary Completion Date (Actual)

2019-04-03

Study Completion Date (Actual)

2024-10-29

Enrollment (Actual)

134

Study Type

Interventional

Phase

Phase 1